{"entity":{"id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of RO7247669 in melanoma, non-small-cell lung cancer and oesophageal cancer, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04140500 by Hoffmann-La Roche, with 170 participants enrolled, started 2019-11-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: RO7247669.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04140500","url":"https://clinicaltrials.gov/study/NCT04140500"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04140500","phase":"1/2","setting":"An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT04140500","source":"https://clinicaltrials.gov/study/NCT04140500","fetchedAt":"2026-10-07T16:53:14.793Z","studySha256":"7dfed3a6ebcfad16bc94ea161d4e4c1893aad929654397b6e78d4d4437331da5","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-11","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":170,"enrolmentType":"ACTUAL","siteCount":25,"recruitingSiteCount":0,"countries":["Denmark","Georgia","Israel","Mexico","Singapore","South Korea","Spain","Turkey (Türkiye)","United Kingdom"]}],"started":"2019-11-11","startedType":"actual","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04140500/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}